IVERIC BIO

DEVELOPING TRANSFORMATIVE THERAPIES
FOR RETINAL DISEASES

July 2022
NASDAQ: ISEE

Forward-looking statements

Any statements in this presentation about IVERIC bio (the Company)'s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about the strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

In this presentation, the Company's forward-looking statements include statements about the hypotheses underlying, the results of and the implications of post-hoc analyses of the Company's GATHER1 clinical trial evaluating Zimura (avacincaptad pegol or ACP) for the treatment of geographic atrophy, the design of, and the timing for receipt of topline data from, the Company's second, Phase 3 trial (GATHER2) evaluating Zimura for the treatment of geographic atrophy, and the potential utility of Zimura. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's research and development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the progress and results of clinical trials and other research and development programs, developments from the scientific and medical community and from the Company's competitors, and other factors discussed in the "Risk Factors" section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission.

Any forward-looking statements represent the Company's views only as of the date of this presentation. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.

Progression of Atrophy in AMD: Post Hoc Analysis From the GATHER1 Study

David R. Lally, MD[1,2]; Jeffrey S. Heier, MD[3]; Srinivas Sadda, MD[4]; David A. Eichenbaum, MD[5]; Carl Danzig, MD[6]

[1]New England Retina Consultants, Springfield, MA, USA; [2]Department of Surgery, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA; [3]Ophthalmic Consultants Of Boston, Boston, MA, USA; [4]Doheny Eye Institute, University Of California, CA, USA; [5]Retina-vitreous Associates Of Florida, Tampa, FL, USA; [6]Rand Eye Institute, Deerfield Beach, FL, USA.

Presented at ASRS 2022 40th Annual Meeting, July 13 – 16, New York City, NY, USA

Financial disclosures

- **David R. Lally**: Affamed Therapeutics (S), Applied Genetic Technologies Corporation (C), Aldeyra Therapeutics (S), Alimera Sciences (C,L), Allergan (C,L), Annexon Biosciences (C,L,S), Apellis Pharmaceuticals (C,S), Chengdu Kanghong Biotechnologies (S), EyePoint Pharmaceuticals (C,S), Genentech (C,L,S), IVERIC Bio (C,L,S), Kodiak Sciences (S), Laboratoires Thea (C), LMRI (S), Neurotech Pharmaceuticals (S), Novartis (C,L,S), Ocuphire Pharma (C,O,S), Opthea (C,S), Outlook Therapeutics (C), Oxurion (S), Regeneron Pharmaceuticals (L), Roche (C), Stealth Biotherapeutics (C,S)
- **Jeffrey S. Heier**: Consulting: 2020 Onsite, 4DMT, Abpro, Adverum, Affamed, AGTC, Akuous, Allegro, Allergan, Annexon, Apellis, Asclepix, Bionic Vision Technologies, Biovisics, Ciana, Curacle, DTx, Gemini, Genenetech, Graybug, Gyroscope, Iveric, Janssen R&D, Kriya, Nanoscope, NGM, Notal Vision, Novartis, OcuTerra, OliX, Palatin, Perceive Therapeutics, Regenxbio, Regeneron, RetinAI, RevOpsis, Stealth Biotherapeutics, Thea, Unity Bio, Vanotech. Research: Annexon, Apellis, AsclepiX, Bayer, Genentech/Roche, Gyroscope, Iveric, jCyte, Kodiak, NGM, Notal Vision, Regeneron, Regenxbio. Equity: Adverum, Aldeyra, Allegro, Aviceda, DTx Pharma, jCyte, Ocular Therapeutix, RevOpsis, Vinci, Vitranu.
- **Srinivas Sadda**: Consultant: Allergan/Abbvie, Regeneron, Roche/Genentech, Novartis, Nanoscope, Apellis, Iveric, Oxurion, Pfizer, Biogen, Jansen, Boerhinger Ingelheim, Amgen, Optos, Heidelberg Engineering, Centervue. Research Instruments: Topcon, Nidek, Carl Zeiss Meditec, Optos, Heidelberg, Centervue. Research Support: Carl Zeiss Meditec. Speaker Fees: Novartis, Heidelberg Engineering, Nidek.
- **David A. Eichenbaum**: 4DMT (I), AsclepiX (I), Genentech (C,I,S), Regeneron (C,I), Bayer (I,S), Allergan (C,S), Clearside (E), Novartis (C,I,S), Alimera (C), Opthea (C,I), Ocular Therapeutix (I), US Retina (E,C), Hemera Biopharmaceuticals (E), Boston Image Reading Center (E), EyePoint (C,I,S), Mylan (I), Chengdu (I; PANDA Trial stopped 04/2021), Gemini (I), Gyroscope (I,C), Kodiak (I,C), NGM (I), Network Eye (E,F), RecensMedical (I,C), DORC (C,S)Alkahest (I), Ionis (I), IvericBio (I,C), Apellis (C,S), KKR (C), Regenxbio (I,C), Bausch & Lomb (C,S), Unity (I), Annexon (I), Vial (C), Coherus (C), Outlook (E)
- **Carl Danzig**: Contracted researcher for Adverum, Bayer, Genentech, Gyroscope, Iveric Bio, Kodiak, Roche, Alexion, and Novartis. Consultant for DORC, Genentech, Iveric Bio, Novartis, Regeneron, and Adverum. Speaker for Genentech and Novartis.

C, consultant; E, equity/stockholder; F, founder; I, investigator; S, speaker.

GATHER1 post hoc analysis: Minimum distance from fovea center

Objective: To assess the effect of avacincaptad pegol on GA lesion growth as a function of minimum distance from the foveal center

- GATHER1 OCT & FAF data was reviewed by Duke Reading Center.
- Images were reviewed from patients who had Heidelberg FAF and Spectralis OCT images at selected study visits (N=205)
  - n=22 avacincaptad pegol 1 mg*
  - n=47 avacincaptad pegol 2 mg
  - n=57 avacincaptad pegol 4 mg
  - n=79 sham
- Minimum distance measured from the closest lesion edge to the foveal center point

*Used in description of baseline lesion location only. Data from these patients was not utilized in building multivariate regression model.
GA, geographic atrophy; FAF, fundus autofluorescence; OCT, optical coherence tomography.
Jaffe GJ. Presented at: RWC. May 13, 2022.

GATHER1 key inclusion and exclusion criteria[1,2]

Key Inclusion Criteria[a]	Key Exclusion Criteria[a]
Male or female aged ≥50 years	CNV in either eye
Nonfoveal GA (non-center point involving GA)[b]	GA secondary to any condition other than AMD in either eye (eg, drug induced)
Total GA area ≥2.5 and ≤17.5 mm^2 (1 and 7 DAs, respectively), determined by screening images of FAF	Any prior treatment for AMD or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals
If GA is multifocal, ≥1 focal lesion should measure ≥1.25 mm^2 (0.5 DA)	Any ocular condition that would progress during the study that could affect central vision or otherwise be a confounding factor
GA in part within 1500 microns from foveal center	
BCVA study eye: 20/25 to 20/320	

[a]Ocular inclusion criteria apply to the study eye.
[b]Nonfoveal GA included lesions inside and outside of the 1.5 mm diameter area of the fovea but not the fovea center point.
AMD, age-related macular degeneration; BCVA, best corrected visual acuity; CNV, choroidal neovascularization; DA, disk area; FAF, fundus autofluorescence; GA, geographic atrophy.

1. Data on file. IVERIC Bio; **2.** Jaffe GJ, et al. *Ophthalmology*. 2021;128:576-586.

IVERIC BIO

Non-foveal was defined as non-center point involving



IVERIC BIO

GA had to be in part within 1500 microns from foveal center point



All patients had to have disease within this circle to be eligible for GATHER1 (and GATHER2)

GA, geographic atrophy.

GATHER1 inclusion/exclusion examples



✓ Included

Within 1500 microns of, but not involving, the foveal center point

IVERIC BIO

GATHER1 inclusion/exclusion examples



✕ Excluded

Foveal center point involvement

IVERIC BIO

GATHER1 inclusion/exclusion examples



✓ Included

Within 1500 microns of, but not involving, the foveal center point

IVERIC BIO

GATHER1 inclusion/exclusion examples



✗ Excluded

Outside of 1500 microns from the foveal center point

IVERIC BIO

~84% of patients had disease within 500 µm of the foveal center point at baseline

Minimum distance from foveal center at baseline



IVERIC BIO

Roughly 1/3 of patients had disease within 100 µm of the foveal center point at baseline

Minimum distance from foveal center at baseline



>0-100 um from foveal center (n=58)

IVERIC BIO

GATHER1 example: Lesion close to fovea







IVERIC BIO

Greater growth reduction with avacincaptad pegol vs sham for patients with lesions farther away from fovea center at Month 18



GA, geographic atrophy; LS, least square.
Jaffe GJ. Presented at: RWC. May 13, 2022.

Ocular treatment emergent adverse events

Patients With ≥1 Event, n (%)	12 Months[1,2,a]			18 Months[1,b]		
	Avacincaptad pegol 2 mg (n=67)	Avacincaptad pegol 4 mg (n=83)	Sham (n=110)	Avacincaptad pegol 2 mg (n=67)	Avacincaptad pegol 4 mg (n=83)	Sham (n=110)
Ocular TEAE (study eye)	35 (52.2)	57 (68.7)	38 (34.5)	39 (58.2)	61 (73.5)	45 (40.9)
Ocular TEAE related to injection procedure	21 (31.3)	42 (50.6)	26 (23.6)	23 (34.3)	46 (55.4)	26 (23.6)
Ocular TEAE related to treatment	0	0[c]	0	0	0	0
Serious ocular TEAE	0	0	0	1 (1.5)	1 (1.2)	0
Severe ocular TEAE	1 (1.5)	1 (1.2)	1 (0.9)	3 (4.5)	1 (1.2)	2 (1.8)
Ocular TEAE leading to study drug discontinuation	0	1 (1.2)	0	1 (1.5)	2 (2.4)	0
Endophthalmitis	0	0	0	0	0	0
Intraocular inflammation related to study drug	0	0	0	0	0	0

[a]TEAEs are AEs occurring after the first injection on Day 1 up to the Month 12 injection or 30 days after the last dose of study drug if no Month 12 injection was given.
[b]TEAEs are AEs occurring after the first injection on Day 1 up to the Month 17 injection + 30 days or 30 days after the last dose of study drug if no Month 17 injection is given.
[c]1 ocular TEAE was noted as related to avacincaptad pegol at Month 12; however, the investigator changed the relationship to "not related" after the closure of the Month 12 database; therefore, no events are presented as related to avacincaptad pegol in the Clinical Study Report.
AE, adverse event; SAE, serious AE; TEAE, treatment-emergent AE.
1. Data on file. IVERIC Bio; **2.** Jaffe GJ, et al. *Ophthalmology.* 2021;128:576-586.

IVERIC BIO

CNV conversion rates were increased with avacincaptad pegol compared with sham[1,2]

	12 Months[1]			18 Months[1]		
	Avacincaptad pegol 2 mg (n=67)	**Avacincaptad pegol 4 mg** (n=83)	**Sham** (n=110)	**Avacincaptad pegol 2 mg** (n=67)	**Avacincaptad pegol 4 mg** (n=83)	**Sham** (n=110)
CNV, n (%)	6 (9.0)	8 (9.6)	3 (2.7)	8 (11.9)	13 (15.7)	3 (2.7)

For reporting purposes, conventional CNV terminology was followed and included **any type of CNV**, including nonexudative lesions, as determined by the investigator

Note: The term CNV is used to describe both Preferred Terms of CNV and nAMD. Review of CNV data revealed that there was an issue with displaying CNV events with an onset at the Month 12 visit (i.e., if the Month 12 visit was >30 days since the last dose of study drug, these events were not counted). Therefore, this table reflects the number of patients with CNV events including those with an onset at Month 12.

CNV, choroidal neovascularization; nAMD, neovascular age-related macular degeneration.

1. Jaffe GJ, et al. *Ophthalmology*. 2021;128(4):576-586; **2.** Data on file. Iveric Bio.

IVERIC BIO

Key takeaways

- Most patients in GATHER1, ~84%, had disease within the central subfield at baseline
  - Roughly 1/3 of all patients had disease within 100 µm of the foveal center point

GA, geographic atrophy.

Key takeaways

- Most patients in GATHER1, ~84%, had disease within the central subfield at baseline
  - Roughly 1/3 of all patients had disease within 100 µm of the foveal center point

- Avacincaptad pegol reduced lesion growth, compared to sham, across all distances from the foveal center point

GA, geographic atrophy.

Key takeaways

- Most patients in GATHER1, ~84%, had disease within the central subfield at baseline
  - Roughly 1/3 of all patients had disease within 100 µm of the foveal center point

- Avacincaptad pegol reduced lesion growth, compared to sham, across all distances from the foveal center point

- The most frequently reported ocular AEs over 18 months in GATHER1 were related to the injection procedure

GA, geographic atrophy.

GATHER2 is a phase 3, international, multicenter, prospective, randomized, double-masked, sham-controlled study[1,2]

Patients will receive intravitreal injections of avacincaptad pegol and/or sham for 24 months (2 years)[1,2]



Year 1 GATHER2 data will be available in the **third quarter of 2022**

FAF, fundus autofluorescence; GA, geographic atrophy; IVT, intravitreal.

1. Data on file. IVERIC Bio; **2.** https://clinicaltrials.gov/ct2/show/NCT04435366. Accessed April 4, 2022. **3.** Iveric Bio press release 04 May, 2022. https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-reports-first-quarter-2022-operational-highlights-and

Thank you to the GATHER program investigators and patients



Acknowledgments

Glenn J. Jaffe, MD conducted the post hoc analysis on minimum distance.

THANK YOU